This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL6R. It is a human monoclonal antibody that can be potentially used in the treatment of Neuromyelitis optica (NMO).
Figure 1 Human Anti-Human IL6R Antibody (AFC-TAB-032ML) in WB
Western blot analysis of AFC-TAB-032ML was performed by loading Human IL6R Protein (His Tag) in reduced condition Lane 1, Lane 2, Lane 3 (0.1 μg, 0.3 μg, 0.6 μg) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-453CT (2 μg/mL) and HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Figure 2 Human Anti-Human IL6R Antibody (AFC-TAB-032ML) in DB
Dot Blot analysis of AFC-TAB-032ML was performed by coating with Human IL6R Protein (His Tag).
AFC-TAB-032ML incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000)
Figure 3 Human Anti-Human IL6R Antibody (AFC-TAB-032ML) in ELISA
ELISA analysis of AFC-TAB-032ML was performed by coating with Human IL6R Protein (His Tag). Then blocked with BSA and incubated with AFC-TAB-032ML. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
DrugMonitor™ Anti-Satralizumab Antibody (VS-1224-YC1063)Satralizumab is a subcutaneously injected anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The DrugMonitor™ Anti-Satralizumab Antibody (VS-1224-YC1063) is an anti-drug antibody (ADA) against Satralizumab. This drug-based antibody is raised in mice immunized with the Satralizumab. The anti-Satralizumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Satralizumab in samples.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-L080E | IL6-PE immunotoxin | Cytotoxicity assay, Functional assay | |
AGTO-L080D | IL6-DT immunotoxin | Cytotoxicity assay, Functional assay |
There are currently no Customer reviews or questions for AFC-TAB-032ML. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.